Grant Application Terms and Conditions


The Incyte Grant for Hematological Research is intended to stimulate the interest for research in the field of hematological malignancies and to encourage young clinicians/researchers to participate in the scientific advancement by supporting the realization of high quality research and development projects.

The following terms and conditions apply to applications submitted for consideration to receive the Incyte Nordic Grant for Hematological Research. By submitting an application, applicant agrees to be bound by these terms and conditions.

On 4 (four) pages:
Project title
Research plan including abstract
Time line of project
Budget, present and applied for

In addition the application should include the following or information thereof (one page only):

Institution/group (if not clear from CV)
If PhD student, certificate from group leader regarding resources and that dissertation is to happen within 18 months from application
List of publications (if not in CV)
Ethics approval

Priority to:
Projects focusing in leukemia or lymphoma
Applicants not more than 3 years after dissertation and maximum 18 months from dissertation

Applications, maximum four (4) pages plus CV (one page), should be sent as an electronic version to:

And one (1) paper copy addressed to:
The Incyte Nordic Grant for Hematological Research
c/o Incyte Biosciences Nordic AB
Barnhusgatan 3
111 23 Stockholm

      1. Applications received after the 1st of October 2024 will not be considered for the 2024 Grant.
      2. Applications should contain a rationale and background of the project, the objectives, a description of methodology, defined timelines and a specified budget (with detailed budget cost breakdown). Max. 4 pages plus one CV page.
      3. A project may be fully or partially funded, but only up to a total of 40.000 USD.
      4. The total Grant funding amount of 40.000 USD may be split between one or more projects.
      5. Grant funding will be limited to actual project costs (per budget breakdown included with application submission).
      6. The following projects will be considered as eligible: preclinical and clinical projects within malignant hematology with a priority for projects focusing on leukemia/lymphoma.
      7. Eligible applicants for the Grant are researchers active at a Nordic unit and performing research primarily taking place in the Nordic region. Priority will be given to applicants scheduled to present their dissertation within the next 18 months or has done so no more than three years ago.
      8. Submissions will be reviewed by a Grant Review Committee consisting of professor Magnus Björkholm (Karolinska Institute – Sweden), professor Kari Remes (Turku University – Finland), Harald Holte, MD, PhD (Oslo University – Norway) and the Medical Director of Incyte Biosciences Nordic AB, the latter without voting rights.
      9. The decision on the award of the Grant will be made by the Grant Review Committee. Such decision is final and binding.
      10. Incyte Biosciences Nordic AB and the Grant Review Committee members may retain a copy of the submitted applications. Submissions will not be returned to applicants.
      11. The applicant’s name and address and a short summary of the project (based on the application) may be publicly communicated/published by Incyte and/or the Grant Review Committee.
      12. The Grant funding will be transferred to a bank account of the institution at which the project will be performed and with which the applicant is affiliated (no payments to personal bank accounts).
      13. Accurate and detailed accounting of use of funds must be kept by recipient and reported to the Grant Committee upon conclusion of the project, or upon request at any time. An assessment of each project and recipient according to national regulations will be made.
      14. Funding may only be used for legitimate and necessary out-of pocket costs associated with proper conduct of the project.
      15. Unused funds at the end of the project must be refunded to Incyte.
      16. No portion of funds to be used to make payments to third parties except as fair market value compensation for legitimate work directly related to the conduct of the project.
      17. A transparency disclosure – “This Project was supported by an unrestricted educational grant by Incyte Biosciences” – will be included in project communications and publications.

The recipient of the Grant commits to report to the Grant Review Committee upon completion of the project Within one year from the receipt of the funds, an interim report is to be submitted to the Committee.